It’s worth noting that the Oxford vaccine can be quickly altered too, as it’s based on a platform technology. They suspect a version with variants can be in production and being rolled out by August.
I wonder though if the really good trial data of the MRNA ones mean they’ll be able to do just safety trials (nothing on effectiveness) in the future, while the Oxford collaboration will be closer scrutinized.
GSK has recently announced plans to produce a multi-valent mRNA vaccine for distribution next year so mRNA is not necessarily limited to a single variant. https://www.gsk.com/en-gb/media/press-releases/gsk-and-curev...